BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ma KP, Fu JX, Duan F, Wang MQ. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(4): 1236-1247 [PMID: 38660650 DOI: 10.4251/wjgo.v16.i4.1236]
URL: https://www.wjgnet.com/1948-5204/full/v16/i4/1236.htm
Number Citing Articles
1
Rui Zhang, Yan-Hui Liu, Yu Li, Nan-Nan Li, Zheng Li. Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinomaWorld Journal of Gastrointestinal Oncology 2024; 16(11): 4315-4320 doi: 10.4251/wjgo.v16.i11.4315
2
Yusuf Ilhan, Yakup Ergun. Maximizing therapeutic outcomes in hepatocellular carcinoma: Insights into combinatorial strategiesWorld Journal of Gastrointestinal Oncology 2024; 16(7): 2888-2893 doi: 10.4251/wjgo.v16.i7.2888
3
Fei-Yu Zhao, Dong-Yu Wang, Nian-Song Qian. Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approachWorld Journal of Gastrointestinal Oncology 2024; 16(10): 4042-4044 doi: 10.4251/wjgo.v16.i10.4042
4
Meer M Chisthi. Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinomaWorld Journal of Gastrointestinal Oncology 2024; 16(7): 2884-2887 doi: 10.4251/wjgo.v16.i7.2884
5
Vishal G Shelat. Improving clinical outcomes of patients with hepatocellular carcinoma: Role of antiviral therapy, conversion therapy, and palliative therapyWorld Journal of Gastrointestinal Oncology 2024; 16(10): 4037-4041 doi: 10.4251/wjgo.v16.i10.4037
6
Natalia Centrone, Pedro Luiz Serrano Uson Junior. Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?World Journal of Gastrointestinal Oncology 2024; 16(12): 4753-4756 doi: 10.4251/wjgo.v16.i12.4753
7
Mao-Ting Zhou, Peng Zhang, Qi Mao, Xiao-Qin Wei, Lin Yang, Xiao-Ming Zhang. Current research status of transarterial therapies for hepatocellular carcinomaWorld Journal of Gastrointestinal Oncology 2024; 16(9): 3752-3760 doi: 10.4251/wjgo.v16.i9.3752